ERYTECH reports positive top-line Phase III results from clinical study with GRASPA® in Acute Lymphoblastic Leukemia admERY September 30, 2014 Newsroom ERYTECH reports positive Phase III results from its pivotal study with GRASPA® in Acute Lymphoblastic Leukemia. You Might Also Like ERYTECH announces clinical trial authorizations in Finland and Spain for its European Phase IIb study in AML January 15, 2014 ERYTECH PHARMA : ANNUAL GENERAL MEETING OF JUNE 24, 2016 June 3, 2016 ERYTECH receives the EnterNext Tech 40 Label April 28, 2015
ERYTECH announces clinical trial authorizations in Finland and Spain for its European Phase IIb study in AML January 15, 2014
